Cardiovascular Research Advance Access [Accepted Manuscript] published online on September 19, 2007
Cardiovascular Research, doi:10.1093/cvr/cvm022
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pro-oxidant Effect of Transforming Growth Factor-ß1 Mediates Contractile Dysfunction in Rat Ventricular Myocytes
1 Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska
2 Department of Cardiology, The First Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215006, P.R. China
3 Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska
4 Center for Redox Biology, University of Nebraska-Lincoln, Lincoln, Nebraska
Address for proofs and reprint requests: George J. Rozanski, Ph.D. Department of Cellular and Integrative Physiology, University of Nebraska College of Medicine, 984575 Nebraska Medical Center, Omaha, NE 68198-4575, (402) 559-6056, FAX# (402) 559-4438, email: grozansk{at}unmc.edu
Objective: Transforming growth factor-ß1 (TGF-ß1) is a multifunctional cytokine that contributes to pathogenic cardiac remodeling via mechanisms that involve oxidative stress. However, the direct impact of TGF-ß1 on contractile function of ventricular myocytes is incompletely understood.
Methods: Reactive oxygen species (ROS) production and intracellular glutathione (GSH) were measured by fluorescence microscopy in isolated rat ventricular myocytes pre-treated with TGF-ß1 (0.1-10 ng/ml). In separate studies, video edge detection measurements were made to evaluate myocyte contractile function, and confocal microscopy was used to monitor evoked Ca2+ transients.
Results: TGF-ß1 (1 ng/ml) for 3-4 h significantly increased ROS production by 90% (p<0.05) and decreased GSH by 34% (p<0.05) compared with control. These changes paralleled a significant decrease in the rate of myocyte shortening and relaxation by 33% and 43%, respectively (0.5 Hz; p<0.05), while fractional shortening was not altered. Ca2+ transients in TGF-ß1-treated myocytes were characterized by a delayed peak and slowing in the rate of decay but no change in peak Ca2+ amplitude. Increased ROS production and GSH depletion by TGF-ß1 were prevented by an NAD(P)H oxidase inhibitor or a free radical scavenger, both of which significantly mitigated TGF-ß1-induced myocyte contractile dysfunction. Moreover, pre-treating myocytes with exogenous GSH or the GSH precursor N-acetylcysteine also prevented myocyte contractile impairment and abnormal Ca2+ transients elicited by TGF-ß1.
Conclusion: Our data suggest that TGF-ß1-induced cardiomyocyte contractile dysfunction is associated with enhanced ROS production and oxidative alterations in Ca2+ handling proteins regulated by endogenous GSH.
Time for primary review: 27 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Li, M.-Q. Zheng, and G. J. Rozanski Glutathione homeostasis in ventricular myocytes from rat hearts with chronic myocardial infarction Exp Physiol, July 1, 2009; 94(7): 815 - 824. [Abstract] [Full Text] [PDF] |
||||
